Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system.

Project Information

CSC-IS

Grant agreement ID: 665671

DOI 10.3030/665671

Closed project

EC signature date 17 June 2015

Start date 1 July 2015

End date 31 December 2016

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 150 000,00

EU contribution € 150 000,00

Coordinated by

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Spain